

LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway

Dong Xue¹ · Cuixing Zhou¹ · Hao Lu¹ · Renfang Xu¹ · Xianlin Xu¹ · Xiaozhou He¹

Received: 17 May 2016 / Accepted: 23 September 2016 / Published online: 14 October 2016
© International Society of Oncology and BioMarkers (ISOBM) 2016

Abstract In prior research, evidence has been found for a relation between low exposure of long non-coding RNAs (lncRNAs) and prostate tumor genesis. This study aims to clarify the underlying mechanisms of lncRNA GAS5 in prostate cancer (PCa). In total, 118 pairs of PCa tissues and matched adjacent non-tumor tissues were collected. Additionally, lncRNA GAS5 exposure levels were determined using RT-PCR and in situ hybridization. In addition, dual-luciferase report assay was performed to verify the target effect of lncRNA GAS5 on miR-103. The exposure levels of the proteins related to the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) axis, including AKT, mTOR, and S6K1, were measured by western blot. PC3 cells infected with lncRNA GAS5 mimic; lncRNA GAS5 siRNA; or a combination of lncRNA and miR-103. The proliferation, invasion, and migration ability of PC3 cells after being infected were tested by MTT assay, wound healing assay, and transwell assays. Finally, nude mouse xenograft models were used to measure lncRNA GAS5 effects on prostate tumor growth in vivo. The lncRNA GAS5 levels were reduced significantly in the PCa tissues and cell lines ($P < 0.05$). A low exposure of lncRNA GAS5 caused AKT/mTOR signaling pathway activation in PC3 cells ($P < 0.05$). In addition, over-exposure of lncRNA GAS5 was proven to significantly decelerate PCa cell progression in vitro and tumor growth in vivo through inactivating the AKT/mTOR signaling pathway ($P < 0.05$). This study proves that lncRNA GAS5 plays a significant role

in the decelerating PCa development via mediating the AKT/mTOR signaling pathway through targeting miR-103.

Keywords Prostate cancer · LncRNA GAS5 · miR-103 · AKT/mTOR signaling pathway · Proliferation · Invasion · Migration · Xenograft model

Introduction

Prostate cancer (PCa) is known as the most prevalent malignancy with male patients, accounting for approximately one fourth of all cancer cases, and the third leading cause of male cancer-related mortality [1]. Over the last years, an increasing incidence of PCa has been observed while the overall 5-year survival rate is decreasing [2]. In addition, it has been proven that the major cause of mortality can be attributed to metastasis [3]. Previous studies have indicated that PCa is able to spread and can seriously effect bones, lungs, liver, pleura, and adrenal glands as well [4]. Therefore, more attention should be paid to further explore the underlying molecular mechanisms involved in the pathogenesis and progression of human PCa. The investigation of the functional networks connecting long non-coding RNAs (lncRNAs) and their downstream targets will provide new insights for developing methods for early diagnostics or non-invasive focal therapies for patients with PCa in the future.

LncRNA is a class of non-protein-coding RNA molecules that include more than 200 nucleotides [5]. Besides, many previous studies found evidence for the fact that lncRNAs are important factors in human carcinogenesis [6]. Among all the known cancer-related lncRNAs, *lncRNA GAS5*—which is a transcript of *growth arrest-specific 5 (gas 5)* gene that contains 12 exons and can encode 10 box C/D snoRNAs via its introns—was first reported by a research of new cancer

✉ Xiaozhou He
xxhehexz@163.com

¹ Department of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu 213003, China

inhibitors in 1988. Since then, lncRNA GAS5 is gaining more and more interest among researchers [7, 8]. LncRNA GAS5 was previously found to show abnormalities in a wide variety of cancer types, such as gastric, cervical, and breast cancer [9–11]. Pickard et al. reported that lncRNA GAS5 is a critical regulator of prostate cell survival and that short-term exposure to lncRNA GAS5 enhances the strength of prostate cells [12]. LncRNA GAS5 was found to be able to interact with a wide range of biomolecules, such as miRNAs which is a class of small, non-coding endogenous RNAs with 21–30 nucleotides in length and regulating protein-coding genes at expression levels [13, 14]. For example, Zhang et al. reported that GAS5 lncRNA is negatively affected by miR-21; interestingly, GAS5 lncRNA itself negatively influences miR-21 which subsequently acts as a reciprocal feedback loop [15].

The protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is a prototypic survival pathway that plays a crucial role in various cellular functions, such as proliferation, growth, survival, and metabolism [16]. Yacqub-Usman et al. previously suggested that mTOR inhibition increased lncRNA GAS5 transcript levels in PCa cell lines, while at the same time GAS5 itself mediates the action of mTOR inhibitors [17]. But to our knowledge, the exact molecular mechanisms between lncRNA GAS5 expression and AKT/mTOR signaling pathway activity in human PCa have not been fully identified yet. miR-103 is a member of the miR-103/107 family located on human chromosome 5 [18]. Recent reports have found that miR-103 expression level was remarkably higher in different types of cancers, including breast, colorectal, and endometrial cancer [19–21]. Also, Li et al. found that miR-103 could function through inactivating the AKT/mTOR signaling pathway [22]. As miR-103 is able to interact with lncRNA GAS5—which is suggested by bioinformatics target gene prediction—we can subsequently hypothesize that lncRNA GAS5 is regulating the AKT/mTOR signaling pathway activity through targeting miR-103, thereby affecting the progression of PCa.

In this research, we aimed to investigate the exposure levels of lncRNA GAS5 in PCa cells and to determine the direct downstream target of lncRNA GAS5. Several experiments have been conducted to detect whether lncRNA GAS5 could successfully suppress PCa cell multiplication and breast tumor genesis by targeting miR-103 through inactivating the AKT/mTOR signaling pathway.

Materials and methods

Patients and specimens

PCa and matched adjacent non-tumor tissues were obtained from 118 randomly selected male patients who underwent radical prostatectomy in the period from 2011 to 2015 at the

Department of Urology, Third Affiliated Hospital, Suzhou University (Changzhou, China). None of the patients has received any previous chemotherapy or radiotherapy, nor was there a history of any other malignant disease. After operation, the tissues were immediately frozen and conserved in liquid nitrogen until further use. The study was approved by the Third Affiliated Hospital, Suzhou University. Prior to tissue collection, all patients were thoroughly informed about the project and signed informed consents. The detailed clinical pathological features of the 118 PCa patients used for this research are summarized in Table 1.

Cell lines and cell culture

Human PCa cell lines (PC3, DU145, and LNCaP) were all acquired from the American Type Culture Collection (ATCC; Shanghai, China). Normal human prostate epithelial cell line RWPE-1 was purchased from the Cell Bank of the Institute of Biochemistry and Cell Biology, CAS (Shanghai, China). All in vitro cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Shanghai) with the addition of 10 % fetal bovine serum (FBS, Gibco, Shanghai) which was contained in a humidified atmosphere with 5 % CO₂ at 37 °C.

In situ hybridization

In situ hybridization was conducted to reveal GAS5 exposure in human prostate specimens based on the manufacturer's guidebook. A digoxigenin (DIG)-labeled antisense LNA probe that has been derived from nt 241–267 was used in this study. The sequence of the specific probe was 5'-TTAC CCAAGCAAGTCATCCATGGATAA-3'. The DIG-labeled

Table 1 Relationship between lncRNA GAS5 expression level and clinical pathological features of prostate cancer patients

Clinical pathological features	LncRNA GAS5 expression level		P value
	Low (≤ 0.55)	High (> 0.55)	
Age (years)			0.580
>66	30	33	
≤ 66	29	26	
PSA level ($\mu\text{g/L}$)			0.003
>10	37	21	
≤ 10	22	38	
Gleason grade			0.038
>7	21	11	
≤ 7	38	48	
Pathologic stage			0.003
I–II	34	49	
III–IV	25	10	

GAS5 probe (1: 400) was hybrid with slices embedded in paraffin at 49.5 °C overnight. After washing and sealing with reagents for a period of 1 h, the sealing reagent was removed and the Tris-buffered saline Tween (TBST) containing anti-DIG antibody (1: 200) was incubated with slices at 37 °C for a period of 1 h as well. The results were observed by microscope after adding a drop of hematoxylin and eosin (H&E).

RNA extraction and RT-PCR

The expression levels of lncRNA GAS5 and miR-103 were detected by quantitative real-time PCR (RT-PCR). Total RNA extraction was conducted using a TRIzol reagent kit (Life Technologies, Inc., Rockville, MD, USA) according to the company's specifications. Then, total RNA was reversely transcribed to complementary DNA (cDNA) using a reverse transcription kit (Bio-Rad, Hercules, California, USA). Additionally, RT-PCR reactions were carried out using a preheated ABI 7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Quantitative measurements were performed using the THUNDERBIRD SYBR® qPCR Mix kit (Toyobo Co., Ltd., Tokyo, Japan). The analysis of relative gene expressions should be performed three times independently, and each sample should be verified in triplicate. Fold changes were determined using relative quantification methods ($\Delta\Delta Ct$). U6 served as internal control. The primer sequences have been listed in Table 2.

Dual-luciferase report assay

The 5' region of miR-103 was mutated using the GeneTailor Site-Directed Mutagenesis System (Invitrogen, USA), and the wild-type or mutated 5' region of miR-103 inserted into the pGL3 promoter vector (Promega Corporation, Madison, WI, USA) was co-transfected with Renilla luciferase vector pRL-SV40 into PC3 cells mediated by Lipofectamine 2000 Transfection Reagent (Invitrogen Corp, CA, USA) in accordance with the manufacturer's instruction book. After incubation for 6 h, the cells were transfected with GAS5 mimic or control. The reporter assay was conducted 42 h post-transfection through the dual luciferase assay system (Promega). The luciferase activity of each sample was normalized to the Renilla luciferase activity.

Plasmid and siRNA transfection

The pcDNA3.1 plasmid (Jikai, Shanghai, China) cloned with a fragment containing the full length of lncRNA GAS5 sequence without a poly-A tail served as GAS5 mimic, and the pcDNA3.1 plasmid cloned with a fragment containing the full length of miR-103 sequence served as miR-103 mimic. The empty pcDNA3.1 plasmid was used as mimic control. The small interfering RNA (siRNA) for lncRNA GAS5 was 5'-CUUGCCUGGACCAGCUUAAAdTdT-3' and 5'-UUCUCCGAACGUGUCACGudTdT-3' was used as siRNA control, which were both acquired from Qiagen (Valencia, CA, USA). The plasmid and siRNA were inserted into PC3 cells using Lipofectamine 2000 reagent, in accordance with the specific manufacturer instructions. After 24h or 48 h after insertion, these PC3 cells were harvested and subsequently utilized for further analysis.

Western blot analysis

Total protein was extracted from the cells using RIPA buffer containing protease inhibitor mixture (Beyotime Institute of Biotechnology, Jiangsu, China). Protein concentration was investigated by a Bradford Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA) based on the manufacturer's instructions. The protein samples with equal amounts (20 µg) were then applied on an SDS-PAGE gel and transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were sealed in TBST containing 5 % non-fat milk, at room temperature for 2 h. After washing the sealed membranes three times with TBST, these were incubated with the specific primary antibodies against AKT, P-AKT, mTOR, P-mTOR, S6K1, and P-S6K1 (diluted with 1:800, 1:500, 1:500, 1:800, 1:800, 1:500, respectively, Zhongshan Biology Company, Beijing) overnight and subsequently incubated with appropriate secondary antibodies (horseradish peroxidase-conjugated goat anti-goat, 1:2000 dilution, Zhongshan Biology Company, Beijing). The membranes were developed using Western chemoluminescent ECL reagent (Tiangen, Beijing, China) and exposed to X-ray film. The density membrane bands were determined by an image

Tab. 2 Quantitative PCR primer sequences

Gene name	Primer sequence
LncRNA GAS5 forward	5'-GTGTGGCTCTGGATAGCAC-3'
LncRNA GAS5 reverse	5'-ACCCAAGCAAGTCATCCATG-3'
miR-103 forward	5'-AAAGGATCCTACTGCCCTCGGCTTCTTAC-3'
miR-103 reverse	5'-AAAGCGGCCCCATTTCCAGTTTTTAAAGTAGAC-3'
U6 forward	5'-CGCTTCGGCAGCACATATACTAAAATTGGAAC-3'
U6 reverse	5'-GCTTCACGAATTTGCGTGTCTCCTTGC-3'

analyzer (LabWorks Software, UVP Upland, CA, USA) with β -actin as the internal control.

Cell proliferation assay

The proliferation of PC3 cells in vitro was measured using the 3-(4,5)-dimethylthiazol (-z-y1)-3,5-diphenyltetrazoliumromide (MTT) assay (Sigma, St. Louis, MO, USA), and all implementations complied with the manufacturer's protocol. PC3 cells were seeded into 96-well plates in a density of 1×10^4 cells/well. After 12, 24, 48, and 72 h of infection, culture medium was replaced with fresh medium containing MTT dye (20 μ l/well) and incubated with the cells for another 4 h. After supernatant removal, dimethyl sulfoxide (DMSO) (150 μ l/well; Sigma, USA) was added and mixed for 15 min. The absorbance value at 450 nm was measured by Universal Microplate Spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT, USA).

Colony formation assay

Six-well plates were coated with 300 μ l of 0.7 % agarose and maintained at 4 °C for 30 min. A density of 1500 PC3 cells per well were suspended in medium containing 0.35 % agarose and placed on plates previously covered with agarose. After 3 weeks of incubation, cells were subsequently fixed with methanol for 15 min. Subsequently, cells were stained with 0.1 % crystal violet for 30 min. Finally, the number of colonies which contained more than 50 cells was counted.

Wound healing assay

Firstly, 8×10^4 PC3 cells/well were seeded in 24-well plates. When the cells reached confluence, the surface of the plates was lightly scratched using a sterile micro pipette tip (Axygen Scientific, Inc., Union City, CA, USA). The floating cells then need to be washed carefully with PBS. An inverted optical microscope (Zeiss, Germany) was used to monitor the closure of the wound at 0, 4, 8, 12, and 16 h. ImageJ software was used to measure the wound area.

Transwell migration and invasion assays

Briefly, 24-well transwell chambers (Costar, Corning, Switzerland) with uncoated or Matrigel-coated membranes were used for migration and invasion assays in this research, respectively. The post-transfected PC3 cells were seeded on the upper chamber which contained the serum-free RPMI 1640 medium, while the RPMI 1640 medium combined with 10 % fetal bovine serum—which acted as chemoattractant—was supplemented to the lower chamber. After incubation for 16 h (migration assay) or 24 h (invasion assay), cells that did

not migrate across the upper surface were removed using a cotton swab, while cells that adhered to the lower surface of the inserts were stained with crystal violet of 0.1 % for 20 min. Finally, the complete filters were washed in water twice before being observed.

Mouse xenograft models

Mouse xenograft models were developed to investigate whether suppression of lncRNA GAS5 could promote tumor genesis through inactivating the AKT/mTOR signaling pathway in vivo. PC3 cells, which were previously mixed with an equal volume Matrigel, were injected subcutaneously in the right flank of 48 6-week-old BALB/c nude mice (Vital River Laboratories Animal, Beijing, China). When the xenografts reached a size of approximately 0.5 cm in diameter, the mice were then randomly divided into six groups (eight mice per group). Twice a week, the tumors of the mice were injected with one of the following: doxorubicin alone (termed as blank), mimic control, GAS5 mimic, siRNA control, GAS5 siRNA, and GAS5 mimic + miR-103 mimic. Tumor growth was measured once a week for a period of 5 weeks by using a caliper. Additionally, the tumor volume was calculated as $\text{length} \times \text{width}^2 / 2$, where length and width meant the biggest and the smallest diameters, respectively. The mice were killed 5 weeks after initial injection. After that, the tumors were extracted, weighed, and snap-frozen for protein extraction. Total protein was isolated from the mouse xenograft tissues for western blot analysis. The Animal Ethics Committee of Fudan University approved all protocols of animal experiments.

Statistical analysis

All statistical analysis of this research was carried out using SPSS 17.0 statistical software (IL, USA). The χ^2 test was applied to analyze the relationship between lncRNA GAS5 expression level and clinical pathological characteristics of PCa patients. All the results which were obtained from the in vitro and in vivo experiments were presented as mean \pm standard deviations, and the data was analyzed by two-sided Student's *t* test. Values of $P < 0.05$ were regarded as statistically significant results in this study.

Results

lncRNA GAS5 expression and clinical pathological features

An analysis was conducted on the relationship between lncRNA GAS5 exposure levels and the clinical pathological characteristics of 118 PCa patients, whose average age was

67.64 ± 8.96 (age range from 46 to 86). Based on the exposure level of lncRNA GAS5, PCa patients were divided into two groups: (1) GAS5-low group including 59 patients (lncRNA GAS5 expression ratio ≤ median ratio) and (2) GAS5-high group including 59 patients (lncRNA GAS5 expression ratio > median ratio). As shown in Table 1, lncRNA GAS5 exposure level in PCa tissues was closely associated to several clinical pathological features of these patients, including PSA level ($P = 0.003$), Gleason grade ($P = 0.038$), and pathological stage ($P = 0.003$). The data indicated that low-level lncRNA GAS5 exposure might correlate with aggressive behaviors of PCa.

lncRNA GAS5 exhibits low expression in both PCa tissues and cell lines

lncRNA GAS5 exposure levels in both PCa tissues and normal tissues were compared through ISH staining and RT-PCR. Compared with corresponding normal tissues, the exposure levels of lncRNA GAS5 were obviously lower in PCa tissues, with an average exposure level of 0.55 compared with normal tissues ($P < 0.05$; Fig. 1a, b). Further investigation in cell lines was carried out subsequently. As demonstrated in Fig. 1c, lncRNA GAS5 also expressed a relatively low level of PC3, DU145, and LNCaP PCa cells in comparison to RWPE-1 normal prostate cells ($P < 0.05$). These results revealed that lncRNA GAS5 was down-regulated in both PCa tissues and cell lines, further revealing that lncRNA GAS5 is likely to have a significant role in prostate tumorigenesis.

miR-103 acts as a direct downstream target of lncRNA GAS5

miR-103 was considered to act as a potential target of lncRNA GAS5 through its 5' region interactions by performing bioinformatics target gene prediction (Fig. 2a). Through measuring the luciferase activity, we found that co-infection of lncRNA GAS5 along with the miR-103 wild-type 5' region resulted in a significant enhancement in luciferase activity compared to that of the control group ($P < 0.05$; Fig. 2b) while co-infection with lncRNA GAS5 along with the miR-103 mutant 5' region did not obviously change luciferase activity. These results revealed that lncRNA GAS5 directly targets miR-103 in PCa cells.

lncRNA GAS5 inactivates Akt/mTOR signaling pathway in PCa cell lines

As appeared in Fig. 3a, lncRNA GAS5 exposure of PC3 cells infected with GAS5 mimic increased significantly by nearly fourfold while infection with GAS5 siRNA obviously down-regulated lncRNA GAS5 exposure ($P < 0.05$). The RT-PCR results also revealed that over-exposure of lncRNA GAS5 would lead to a significant drop of miR-103 exposure by approximately half ($P < 0.05$; Fig. 3b). Besides, co-infection with miR-103 mimic could recover the low exposure levels of miR-103 caused by infection of GAS mimic. However, it could not recover the high exposure levels of lncRNA GAS5 caused by infection of GAS mimic. Moreover, in order to




Fig. 1 lncRNA GAS5 exhibits low level expression in PCa tissues and cell lines. **a** lncRNA GAS5 expression level was investigated in 118 pairs of PCa tissues (I) and matched non-tumor tissues (II) using in situ hybridization. **b** lncRNA GAS5 expression level was investigated in PCa tissues and matched non-tumor tissues through RT-PCR. **c** Relative

expression levels of lncRNA GAS5 were detected in PC3, DU145, and LNCaP PCa cells in comparison with RWPE-1 normal prostate cells using RT-PCR. lncRNA GAS5 data were expressed as the mean ± standard deviation. Similar results were obtained from three independent experiments ($P < 0.05$ vs. RWPE-1 group)




Fig. 2 miR-103 is a direct target of lncRNA GAS5. **a** The lncRNA GAS5-binding sequence in the 5' region of miR-103. A mutation was generated in the miR-103 5' region sequence in the complementary site for the seed region of lncRNA GAS5, as shown. **b** PC3 cells were transfected with either the wild-type or mutant 5' region of miR-103, together with GAS5 mimic or control. After 48 h, the relative luciferase values were measured and normalized by Renilla luciferase activity. All data were expressed as the mean \pm standard deviation. Similar results were obtained from three independent experiments (* $P < 0.05$)

explore the relationship between lncRNA GAS5 and the AKT/mTOR signaling pathway in PCa cells, western blot analysis was conducted to detect phosphorylation of related AKT/mTOR pathway proteins, including AKT, mTOR, and S6K1. As demonstrated in Fig. 3c, compared to other groups of cells, the PC3 cells infected with GAS5 mimic alone had significantly decreased P-AKT, P-mTOR, and P-S6K1 exposure levels. Furthermore, the exposures of AKT, mTOR, and S6K1 were up-regulated, whereas phosphorylation of relative proteins in AKT/mTOR, the signaling pathway in PC3 cells, was observed when lncRNA GAS5 was down-regulated (all $P < 0.05$). In contrast, the P-AKT, P-mTOR, and P-S6K1 exposure levels of the PC3 cells which were co-infected with GAS5 mimic and miR-103 mimic were not obviously different from those in other group of cells. All these data indicated that lncRNA GAS5 was able to inactivate AKT/mTOR's signaling pathway through targeting miR-103 in PCa cell lines.

lncRNA GAS5 inhibits PCa cell progression through targeting miR-103 in vitro

Whether lncRNA GAS5 could affect cell proliferation by targeting miR-103 in vitro was verified through conducting an MTT growth assay over a 72-h period. As demonstrated in Fig. 4a, lncRNA GAS5 over-exposure was found to remarkably down-regulate cell proliferation while infection with GAS5

siRNA could increase the proliferation rates obviously ($P < 0.05$), which indicated that PCa cell proliferation ability was significantly associated with the relatively down-regulated level of lncRNA GAS5. The over-exposure of miR-103 could fully rescue the effect contributed by the up-regulation of lncRNA GAS5. In addition, the colony formation assay exhibited that lncRNA GAS5 siRNA increased the number of colonies of PC3 cells in comparison to other groups (Fig. 4b).

Furthermore, we discovered that the migration and invasion status of lncRNA GAS5 over-exposure cells were dramatically impaired in comparison to that of other groups. As revealed by wound healing assay, cells infected with GAS5 mimic moved significantly slower during a period of 16 h ($P < 0.05$; Fig. 4c). Meanwhile, transwell assays also confirmed that the cells with lncRNA GAS5 up-regulation showed a robust decrease in cell migration and invasion status, whereas infection with GAS5 siRNA greatly increased the migration and invasion status of PC3 cells ($P < 0.05$; Fig. 4d, e).

lncRNA GAS5 inhibits PCa in vivo through inactivating the AKT/mTOR signaling pathway

The influence of lncRNA GAS5 on tumor growth in vivo was evaluated by mouse PC3 transplantation tumor models, and all mice developed detectable xenograft tumors at the injection site. As demonstrated in Fig. 5a, tumor growth in the mice treated with GAS5 mimic was significantly lower than in other groups of mice ($P < 0.05$). Five weeks after injection, as shown in Fig. 5b, the average tumor weight in the GAS5 mimic group (199.8 ± 55.6 mg) was remarkably lower compared to other groups of mice ($P < 0.05$). Representative tumor nodules were presented in Fig. 5c. These results presented that lncRNA GAS5 had an effect on inhibiting tumor growth in vivo significantly. Moreover, the exposure of AKT, mTOR, and S6K1 at total and phosphorylation protein levels in mouse xenografts was investigated by western blot analysis. In comparison to other groups, AKT, mTOR, and S6K1 were all less phosphorylated in the mouse xenografts which were injected with GAS5 mimic ($P < 0.05$; Fig. 5d).

Discussion

The exploration of lncRNAs has greatly accelerated our understanding of the underlying mechanisms that regulate gene exposure in human diseases, particularly cancers [23]. Several lncRNAs have been recently considered as important regulators of gene exposure in human PCa due to their aberrant exposure in PCa tissue samples or PCa cell lines. For instance, lncRNA MEG3 has been reported to suppress cell proliferation and induce apoptosis in PCa [24]. Furthermore, lncRNA




Fig. 3 LncRNA GAS5 inactivates the AKT/mTOR signaling pathway in PCa cell lines. **a** LncRNA GAS5 expression levels of PCa cells after transfection were investigated by RT-PCR. **b** miR-103 expression levels of PC3 cells after transfection were investigated by RT-PCR. **c** AKT,

mTOR, and S6K1 expressions were investigated through Western blot at total and phosphorylation protein levels. All the data represent the mean \pm standard deviation. Similar results were obtained from three independent experiments (* $P < 0.05$)

PCAT-1 has been investigated to promote PCa cell proliferation [25].

LncRNA GAS5 was first isolated from a screen with the purpose of finding a potential cancer inhibitor gene expressed at high levels during cell growth arrest, induced after serum starvation [8]. Accumulating studies have suggested that lncRNA GAS5 is remarkably associated to a wide variety of human carcinomas, such as the human breast, stomach, gastric, and hepatocellular carcinoma [9, 11, 26, 27]. Liu et al. found that lncRNA GAS5 inhibits proliferation of bladder cancer cells through regulating CDK6 exposure [28]. Pickard et al. reported that lncRNA GAS5 promotes the apoptosis in PCa cell lines [12]. In this report, situ hybridization and RT-PCR enabled us to discover that lncRNA GAS5 is clearly down-regulated in human PCa tissues in comparison to matched normal prostate tissues. Furthermore, PCa cell lines also exhibited remarkably low expression levels of lncRNA GAS5 compared to normal prostate cells. The results were consistent to the previous studies [29, 30]. Therefore,

what we have found indicates that lncRNA GAS5 might have an effect on the progression of PCa.

Current studies have indicated that several bio-molecules, including miR-222, YBX1, and Notch-1, have high correlations with the lncRNA GAS5 exposure [26, 31, 32]. In those studies, we found the lncRNA GAS5 binding sites in the 5' regions of miR-103 through bioinformatics target gene prediction, and dual-luciferase report assay was subsequently designed and performed to further confirm that lncRNA GAS5 directly targets miR-103, a type of microRNA which is also closely associated with various human carcinogenesis [20, 33].

The mTOR, a serine/threonine protein kinase regulated by protein kinase B (AKT), plays a vital role in transcription, translation, protein synthesis, cell growth, proliferation, apoptosis, and metabolism, and it is constitutively activated in various types of human cancers, such as lung, ovarian, and pancreatic carcinomas [34–36]. Rapamycin, an mTOR inhibitor, was able to both increase lncRNA GAS5 expression levels and suppress the growth of hormone-sensitive cell lines,




Fig. 4 LncRNA GAS5 suppresses PCa cell proliferation, invasion, and migration through targeting miR-103 in vitro. **a** PC3 cell growth rates in vitro was measured by MTT assay. **b** Colony formation of PC3 cells after transfection as indicated before. **c** PC3 cells were tested by performing wound healing assays with a 16-h recovery period. **d** PC3

cell migration ability was assessed using transwell assay after transfection as indicated before. **e** PC3 cell invasion ability was assessed using transwell assay after transfection as indicated before. All the data represent the mean \pm standard deviation. Similar results were obtained from three independent experiments (* $P < 0.05$)




Fig. 5 LncRNA GAS5 suppresses PCa tumor growth in vivo through inactivating the AKT/mTOR signaling pathway. **a** Tumor growth curves in nude mice. **b** Mice were killed 5 weeks after initial injection and tumors were extracted and weighed. **c** Representative tumor nodules. **d** AKT, mTOR, and S6K1 in mouse xenografts were detected through western blot at total and phosphorylation protein levels. All the data represent the mean \pm standard deviation ($*P < 0.05$)

such as breast cancer cells and PCa cells [17, 37], indicating that lncRNA exposures may be associated with mTOR activation in PCa. The AKT-mTOR signaling pathway is located at a critical interface where intracellular and extracellular signals directly impact various important cellular processes. Taylor et al. revealed that alterations in the AKT/mTOR signaling pathway have been found in 42 % of primary prostate tumors and 100 % of metastatic tumors [38], which indicates that alterations in this signaling pathway may be a prerequisite for the development of PCa. But to our knowledge, there was still little known about the underlying interaction between the lncRNA GAS5 exposure and the AKT/mTOR signaling pathway activation in PCa. In this research, the exposure levels of the main components of the AKT/mTOR signaling pathway, including AKT, mTOR, and S6K1, all of which are tumor-related genes, were assessed at total and at phosphorylation protein levels in vitro and in vivo. Our experimental data revealed that lncRNA GAS5 over-exposure resulted in significantly reduced phosphorylation of AKT, mTOR, and S6K1 proteins, further indicating that lncRNA GAS5 can lead to inactivate the AKT/mTOR signaling pathway. In addition,

over-exposure of miR-103 could fully rescue the effect on the proteins related to the AKT/mTOR axis, including AKT, mTOR, and S6K1 contributed by the up-regulation of lncRNA GAS5, which suggests that miR-103 might be a mediator for lncRNA GAS5 and the AKT/mTOR signaling pathway. Previous studies also indicated that miR-103 could function through activating the AKT/mTOR signal pathway [22]. Therefore, it could be concluded that up-regulation of lncRNA GAS5 could inactivate the AKT/mTOR signaling pathway through targeting miR-103.

It was reported that low exposure levels of lncRNA GAS5 could predict poor overall survival in a wide variety of cancers, and in comparison to a high lncRNA GAS5 exposure, low exposure of lncRNA GAS5 was significantly related to distant metastasis and lymph node metastasis of cancers [39]. Qiao et al. found that an over-exposure of GAS5 inhibited proliferation, migration, and invasion potential in renal carcinoma cell lines [40]. Whether lncRNA GAS5 could target miR-103 to have an impact on the proliferation, invasion, and migration abilities of PCa cell lines, which are closely related to PCa metastasis, was investigated in our current

research. It showed that the up-regulation of lncRNA GAS5 could significantly suppress the capacity of cell proliferation, invasion, and migration for PCa cells, which was correlated to the inactivation of the AKT/mTOR signaling pathway [38]. In addition, according to our *in vivo* experiments, we can conclude that the lncRNA GAS5 over-exposure could suppress PCa tumor growth *in vivo* through inactivating the AKT/mTOR signaling pathway.

However, there are still several limitations in our study which need to be mentioned here. For example, our sample population of PCa patients is relatively small for analysis and therefore selection bias may have occurred. In addition, in the future study, we would plan to collect serum and plasma samples of PCa patients and healthy people for the purpose of further identifying the relationship between lncRNA GAS5 and the AKT/mTOR signaling pathway in PCa.

In summary, up-regulation of lncRNA GAS5 can negatively mediate the AKT/mTOR signaling pathway through directly targeting miR-103, thereby inhibiting the pathogenesis and progression of PCa. Thus, our findings may not only provide a molecular basis for the role of lncRNA GAS5 in PCa but also indicate a novel biomarker for PCa screening and therapeutic targets for effectively managing PCa patients.

Acknowledgments This work was supported by Changzhou Municipal Science and Technology Bureau Support Project (CE20135046) and Jiangsu Provincial Health Department General Research Project (H201348).

Compliance with ethical standards The Animal Ethics Committee of Fudan University approved all protocols of animal experiments.

Conflicts of interest None

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65:5–29.
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin.* 2014;64:252–71.
- Jilg CA, Ketschek M, Metzger E, et al. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. *Oncotarget.* 2014;5:12646–64.
- Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. *Hum Pathol.* 2000;31:578–93.
- Chihara S, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett.* 2013;339:159–66.
- Yuan J, Yue H, Zhang M, et al. Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer. *Oncotarget.* 2016;7:8131–42.
- Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. *Mol Cell Biol.* 1998;18:6897–909.
- Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. *Cell.* 1988;54:787–93.
- Sun M, Jin FY, Xia R, et al. Decreased expression of long noncoding RNA gas5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. *BMC Cancer.* 2014;14:319.
- Cao S, Liu W, Li F, et al. Decreased expression of lncRNA gas5 predicts a poor prognosis in cervical cancer. *International journal of clinical and experimental pathology.* 2014;7:6776–83.
- Mourtada-Maarabouni M, Pickard MR, Hedge VL, et al. Gas5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. *Oncogene.* 2009;28:195–208.
- Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA gas5 regulates apoptosis in prostate cancer cell lines. *Biochim Biophys Acta.* 2013;1832:1613–23.
- Pickard MR, Williams GT. Molecular and cellular mechanism of action of tumour suppressor gas5 lncRNA. *Genes.* 2015;6:184–99.
- Zhao X, Wang P, Liu J, et al. Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-212. *Molecular therapy : the journal of the American Society of Gene Therapy.* 2015;23:1899–911.
- Zhang Z, Zhu Z, Watabe K, et al. Negative regulation of lncRNA gas5 by miR-21. *Cell Death Differ.* 2015;20:1558–68.
- Hay N. The Akt-mTOR tango and its relevance to cancer. *Cancer Cell.* 2005;8:179–82.
- Yacqub-Usman K, Pickard MR, Williams GT. Reciprocal regulation of gas5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. *Prostate.* 2015;75:693–705.
- Landgraf P, Rusch M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell.* 2007;129:141–48.
- Martello G, Rosato A, Ferrari F, et al. A microRNA targeting dicer for metastasis control. *Cell.* 2010;141:1195–207.
- Nonaka K, Miyake Y, Hata T, et al. Circulating miR-103 and miR-100 as novel serum biomarkers for patients with colorectal cancer. *Int J Oncol.* 2015;47:1097–102.
- Yu D, Zhou H, Xun Q, et al. MicroRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. *Oncol Lett.* 2012;3:1221–6.
- Li M, Liu Z, Zhang Z, et al. Mir-103 promotes 3t3-l1 cell adipogenesis through AKT/mTOR signal pathway with its target being MEF2D. *Biol Chem.* 2015;396:235–44.
- Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. *RNA Biol.* 2012;9:703–19.
- Luo G, Wang M, Wu X, et al. Long non-coding RNA MEG3 inhibits cell proliferation and induces apoptosis in prostate cancer. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.* 2015;37:2209–20.
- Prensner JR, Chen W, Han S, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. *Neoplasia.* 2014;16:900–8.
- Liu Y, Zhao J, Zhang W, et al. LncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. *Scientific reports.* 2015;5:10159.
- Chang L, Li C, Lan T, et al. Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. *Mol Med Rep.* 2016;13:1541–50.
- Liu Z, Wang W, Jiang J, et al. Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. *PLoS One.* 2013;8:e73991.
- Shain SA. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2. *Molecular cancer research : MCR.* 2004;2:653–61.

30. Romanuik TL, Wang G, Morozova O, et al. LNCaP atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. *BMC Med Genet.* 2010;3:43.
31. Yu F, Zheng J, Mao Y, et al. Long non-coding RNA growth arrest-specific transcript 5 (GAS5) inhibits liver fibrogenesis through a mechanism of competing endogenous RNA. *J Biol Chem.* 2015;290:28286–98.
32. Pei J, Wang B. Notch-1 promotes breast cancer cells proliferation by regulating lncRNA GAS5. *Int J Clin Exp Med.* 2015;8:14464–71.
33. Xia W, Ni J, Zhuang J, et al. Mir-103 regulates hepatocellular carcinoma growth by targeting AKAP12. *Int J Biochem Cell Biol.* 2016;71:1–11.
34. Barrett D, Brown VI, Grupp SA, et al. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. *Paediatric drugs.* 2012;14:299–316.
35. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes Dev.* 2004;18:1926–45.
36. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol.* 2009;10:307–18.
37. Pickard MR, Williams GT. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. *Breast Cancer Res Treat.* 2014;145:359–70.
38. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell.* 2010;18:11–22.
39. Song W, Wang K, Zhang RJ, et al. Long noncoding RNA GAS5 can predict metastasis and poor prognosis: a meta-analysis. *Minerva Med.* 2016;107:70–6.
40. Qiao HP, Gao WS, Huo JX, et al. Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. *Asian Pacific journal of cancer prevention : APJCP.* 2013;14:1077–82.

RETRACTED ARTICLE